WallStreetZenWallStreetZen

NASDAQ: GYRE
Gyre Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Gyre Therapeutics revenue was $102.19M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $26.8M, up 21.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GYRE annual revenue was $105.8M, with -6.8% growth year-over-year.

GYRE past revenue growth

How has GYRE's revenue growth performed historically?

Company
-8.42%
Industry
150.53%
Market
20.47%
GYRE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
GYRE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
GYRE's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

GYRE revenue history

Current Revenue
$102.2M
Current Earnings
$4.2M
Current Profit Margin
4.1%

Be the first to know when GYRE announces revenue.

GYRE Revenue History By Year

GYRE Yearly RevenueGYRE RevenueGYRE ChangeGYRE Revenue Growth
2024-12-31$105.76M-$7.69M-6.78%
2023-12-31$113.45M$11.16M+10.91%
2022-12-31$102.29M$94.95M+1,293.98%
2021-12-31$7.34M-$13.61M-64.97%
2020-12-31$20.95MN/AN/A
2019-12-31$0.00N/AN/A
2018-12-31$0.00-$1.02M-100.00%
2017-12-31$1.02M$619.00k+155.14%
2016-12-31$399.00k-$1.35M-77.20%
2015-12-31$1.75M-$63.00k-3.47%
2014-12-31$1.81M$1.29M+246.65%
2013-12-31$523.00k-$57.34M-99.10%
2012-12-31$57.86M-$39.78M-40.74%
2011-12-31$97.64M$11.92M+13.91%
2010-12-31$85.71M$60.65M+242.00%
2009-12-31$25.06M$4.98M+24.78%
2008-12-31$20.09M$8.51M+73.51%
2007-12-31$11.58M-$15.96M-57.96%
2006-12-31$27.54M$26.36M+2,233.81%
2005-12-31$1.18M-$2.56M-68.44%
2004-12-31$3.74M$1.28M+52.07%
2003-12-31$2.46MN/AN/A

1 of 2

Gyre Therapeutics Revenue FAQ

What was GYRE's revenue last quarter?

On Invalid Date, Gyre Therapeutics (NASDAQ: GYRE) reported Q2 2025 revenue of $26.77 million up 6.13% year over year. In the same quarter last year, Gyre Therapeutics's revenue was $25.23 million.

What was Gyre Therapeutics's revenue in 2024?

Gyre Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $105.76 million, a 6.78% decrease year over year.

How much does Gyre Therapeutics make in a day?

Based on Gyre Therapeutics annual revenue for the past five years, GYRE makes an average of $191,661.92 per day.

What was Gyre Therapeutics's annual revenue growth in the past year?

As of Q4 2025, Gyre Therapeutics's revenue has grown -8.42% year over year. This is 158.95 percentage points lower than the US Biotechnology industry revenue growth rate of 150.53%. Gyre Therapeutics's revenue in the past year totaled $102.19 million.

How much does Gyre Therapeutics make in a year?

Gyre Therapeutics's revenue by year for the past five years is:
  • Gyre Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $105.76 million, a 6.78% decrease year over year.
  • Gyre Therapeutics's annual revenue for Dec 31, 2023 was $113.45 million, a 10.91% increase from 2022.
  • Gyre Therapeutics's annual revenue for 2022 was $102.29 million, a 1,293.98% increase from 2021.
  • Gyre Therapeutics's annual revenue for 2021 was $7.34 million, a 64.97% decrease from 2020.
  • Gyre Therapeutics's annual revenue for 2020 was $20.95 million, a Infinity% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.